Harmony Biosciences, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, completed the acquisition of Zynerba Pharmaceuticals, a provider of innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, for $200m. "Zygel is a significant market opportunity that advances our long-term growth strategy of developing a diversified portfolio beyond sleep/wake therapies.This acquisition expands our pipeline with a product candidate in our area of expertise that could address high unmet medical needs for people living with rare neuropsychiatric disorders," Jeffrey M. Dayno, Harmony Biosciences President and CEO.